1606 Corp pivots to AI chatbots but has no revenue, $1.74M related‑party note raises going‑concern

1606 Corp. (PINK: CBDW) - Q2 2025 snapshot

What's happening inside
- The company has pivoted to AI chatbot products for the CBD industry and public companies (ChatCBDW, Chat IR) but has not yet converted that technology into meaningful revenue.
- Management is funding operations with short‑term financing (related‑party promissory notes, convertible notes and stock issuances). There is substantial doubt about the company's ability to continue as a going concern without additional funding.

Key facts & statistics
- Cash (June 30, 2025): $1,863.
- Total assets: $26,764.
- Total current liabilities: $2,569,614; Total liabilities: $2,569,614.
- Stockholders' deficit: $(2,542,850); Accumulated deficit: $(7,355,452).
- Accounts payable and accrued liabilities: $567,969; Accrued interest: $19,618.
- Note payable to shareholder (related party): $1,739,550 (due Dec 31, 2025; non‑interest bearing per disclosure).
- Convertible notes, net of discount: $55,459; Derivative liability: $123,562.
- Common shares outstanding (June 30, 2025): 164,261,130.
- Weighted average common shares (three months ended): 144,333,872.

Income statement - positives
- Operating expense control: SG&A fell materially year over year - Three months SG&A $117,084 (Q2 2025) vs $288,739 (Q2 2024); Six months $291,316 vs $686,660 - shows cost reduction.
- Net loss narrowed: Three months net loss $(210,111) vs $(339,192) prior year; Six months $(418,450) vs $(625,629) - smaller losses driven mainly by lower operating fees.
- Non‑cash benefits: Company recognized a gain on debt extinguishment of $47,046 (six months) and a favorable change in fair value of derivative liabilities of $93,721 (six months), which reduced reported loss for the period.
- Financing activity provided cash stability in the period: net cash provided by financing $276,470 (six months), including $374,000 from shareholder note proceeds and $71,092 from common stock sales.

Income statement & financial statement - negatives / risks
- No meaningful revenue: Revenue was $0 for the three and six months ended June 30, 2025 (six months 2024 revenue was only $7,195). Product/recurring licensing revenue has not materialized.
- Severe liquidity mismatch: $26,764 in assets vs $2.57M liabilities; extremely limited cash ($1,863) versus near‑term debt maturities totaling $1,918,350 scheduled for 2025 per the filing.
- Heavy related‑party debt concentration: $1.74M promissory note to a former CEO/shareholder - creates refinance/default and related‑party risk.
- Convertible instruments & derivatives create dilution and volatility: derivative liability $123,562, convertible notes with low conversion prices and short terms; potential for large share issuance (Class A preferred convertible into 25 common shares each).
- Ongoing interest burden: interest expense materially reduced but still $(125,175) for six months; accrued interest present and convertible note interest rates 8-13%.
- Going concern: Management states need of approximately $1,000,000 to continue operations for 12 months - substantial doubt disclosed.
- Governance & control weaknesses: Management concluded disclosure controls were not effective - material weaknesses: lack of functioning audit committee and inadequate segregation of duties; CEO also serves as CFO (concentration of control).

Operational & strategic issues
- Product development: AI chatbot tech appears built and integrated with ChatGPT and Azure; beta deployments (Cool Blue Distribution) and technical partnerships exist, but commercial traction/recurring licensing sales are not yet realized.
- Inventory: Company stopped selling CBD products and wrote off remaining inventory (September 2024), so revenue must come from BOT services moving forward.
- Dilution risk: large numbers of convertible preferred shares (58,237,951 Class A preferred outstanding at June 30, 2025, convertible into common) and prior conversions materially increased common share count during H1 2025.

Bottom line - investor takeaways
- The company has technology and partnerships but no current revenue runway; financials show acute liquidity stress and heavy related‑party funding.
- Cost reductions narrowed losses, but absence of recurring revenue and the $1.74M shareholder note due before year‑end create urgent refinancing/dilution risk.
- Material weaknesses in controls and concentrated insider influence increase operational and governance risk.
- Key catalysts to watch: (1) any signed recurring licensing contracts or BOT client revenue, (2) refinancing or repayment of the $1.74M shareholder note, (3) successful non‑dilutive capital raise of ~$1M, and (4) remediation of governance weaknesses.

Short, factual summary based on the 10‑Q for the quarter ended June 30, 2025.